secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001193125-25-114891
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno Q1 net loss $43.8M; VYKAT XR launch: 268 patient forms, 131 prescribers
------------------------------------------------------------------------------

- VYKAT XR approved by FDA Mar 26; treatments started Apr 14; 268 patient start forms and 131 prescribers through May 6.
- Q1 net loss $43.8M ($0.95 EPS) vs $21.4M ($0.59) a year ago; no revenue yet.
- Cash and marketable securities $290.0M; operating cash use $32.8M in quarter.
- R&D expense $13.5M; SG&A $29.3M, reflecting launch preparation costs.
- MAA submission to EMA for DCCR on track for Q2 2025; contingent consideration liability $17.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525114891/0001193125-25-114891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525114891/d56501d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-114891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer